• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性血液交换输血治疗镰状细胞病并发毛细血管前性肺动脉高压。

Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease.

机构信息

Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.

AP-HP, Service de Pneumologie, Centre de Référence de l'Hypertension Pulmonaire Sévère, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.

出版信息

Eur Respir J. 2018 Oct 10;52(4). doi: 10.1183/13993003.00272-2018. Print 2018 Oct.

DOI:10.1183/13993003.00272-2018
PMID:30305330
Abstract

The long-term effects of chronic blood exchange transfusions (BETs) on pre-capillary pulmonary hypertension complicating sickle cell disease (SCD) are unknown.13 homozygous SS SCD patients suffering from pre-capillary pulmonary hypertension and treated by chronic BETs were evaluated retrospectively. Assessments included haemodynamics, New York Heart Association Functional Class (NYHA FC), 6-min walk distance (6MWD) and blood tests.Before initiating BETs, all patients were NYHA FC III or IV, median (range) 6MWD was 223 (0-501) m and median (range) pulmonary vascular resistance (PVR) was 3.7 (2-12.5) Wood Units. After a median number of 4 BET sessions, all patients had improved to NYHA FC II or III. Significant improvements in haemodynamics were observed, including a decrease in PVR (p=0.01). There was a trend to higher 6MWD (p=0.09). Median (range) follow-up time after initiation of BETs was 25 (6-53) months. During this period, two patients decided to stop BETs. One of them died from acute right heart failure and the other experienced worsening pulmonary hypertension. Two other patients died during follow-up at 25 and 54 months after BET initiation.Chronic BETs may be a potential therapeutic option in pre-capillary pulmonary hypertension complicating SCD, leading to significant clinical and haemodynamic improvements. These data must be confirmed in a prospective study.

摘要

慢性血液交换输血 (BET) 对镰状细胞病 (SCD) 并发毛细血管前肺动脉高压的长期影响尚不清楚。13 例接受慢性 BET 治疗的纯合 SS SCD 并发毛细血管前肺动脉高压患者进行回顾性评估。评估包括血流动力学、纽约心脏协会功能分级(NYHA FC)、6 分钟步行距离(6MWD)和血液检查。在开始 BET 之前,所有患者均为 NYHA FC III 或 IV 级,中位(范围)6MWD 为 223(0-501)m,中位(范围)肺血管阻力(PVR)为 3.7(2-12.5)Wood 单位。中位 4 次 BET 治疗后,所有患者均改善至 NYHA FC II 或 III 级。观察到血流动力学显著改善,包括 PVR 降低(p=0.01)。6MWD 有升高趋势(p=0.09)。BET 开始后中位(范围)随访时间为 25(6-53)个月。在此期间,2 例患者决定停止 BET。其中 1 例死于急性右心衰竭,另 1 例发生肺动脉高压恶化。另外 2 例患者分别在 BET 开始后 25 个月和 54 个月时死亡。慢性 BET 可能是 SCD 并发毛细血管前肺动脉高压的潜在治疗选择,可显著改善临床和血流动力学。这些数据必须在前瞻性研究中得到证实。

相似文献

1
Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease.慢性血液交换输血治疗镰状细胞病并发毛细血管前性肺动脉高压。
Eur Respir J. 2018 Oct 10;52(4). doi: 10.1183/13993003.00272-2018. Print 2018 Oct.
2
Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.波生坦用于治疗与先天性心脏病相关的肺动脉高压。
Eur J Clin Invest. 2006 Sep;36 Suppl 3:25-31. doi: 10.1111/j.1365-2362.2006.01685.x.
3
A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension.一项前瞻性研究表明,6 分钟步行试验可作为未经治疗的系统性硬化症相关肺动脉高压两个独立队列中血液动力学的替代标志物。
Ann Rheum Dis. 2016 Aug;75(8):1457-65. doi: 10.1136/annrheumdis-2015-207336. Epub 2015 Aug 31.
4
Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.静脉注射依前列醇治疗无法手术的慢性血栓栓塞性肺动脉高压
J Heart Lung Transplant. 2007 Apr;26(4):357-62. doi: 10.1016/j.healun.2006.12.014.
5
Paediatric sickle cell disease: pulmonary hypertension but normal vascular resistance.儿科镰状细胞病:肺动脉高压但血管阻力正常。
Arch Dis Child. 2011 Feb;96(2):131-6. doi: 10.1136/adc.2010.184028. Epub 2010 Oct 27.
6
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.波生坦一线治疗特发性肺动脉高压的长期疗效
Eur Heart J. 2006 Mar;27(5):589-95. doi: 10.1093/eurheartj/ehi728. Epub 2006 Jan 23.
7
Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.波生坦作为一线单药治疗系统性硬皮病相关肺动脉高压的长期疗效,是否联合前列环素或西地那非。
Rheumatology (Oxford). 2010 Mar;49(3):490-500. doi: 10.1093/rheumatology/kep398. Epub 2009 Dec 16.
8
Pathophysiology and treatment of pulmonary hypertension in sickle cell disease.镰状细胞病中肺动脉高压的病理生理学与治疗
Blood. 2016 Feb 18;127(7):820-8. doi: 10.1182/blood-2015-08-618561. Epub 2016 Jan 12.
9
Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease.镰状细胞病毛细血管前性肺动脉高压的临床表型和结局。
Eur Respir J. 2019 Dec 4;54(6). doi: 10.1183/13993003.00585-2019. Print 2019 Dec.
10
Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.与皮下注射曲前列尼尔治疗的肺动脉高压患者生存改善相关的预后因素:随机、安慰剂对照试验。
J Heart Lung Transplant. 2011 Sep;30(9):982-9. doi: 10.1016/j.healun.2011.03.011. Epub 2011 May 4.

引用本文的文献

1
Pulmonary Hypertension in Sickle Cell Disease: A Case Series.镰状细胞病中的肺动脉高压:病例系列
Cureus. 2025 Jul 29;17(7):e89012. doi: 10.7759/cureus.89012. eCollection 2025 Jul.
2
Pulmonary Hypertension in Sickle Cell Disease: Novel Findings of Gene Polymorphisms Related to Pathophysiology.镰状细胞病中的肺动脉高压:与病理生理学相关的基因多态性的新发现。
Int J Mol Sci. 2024 Apr 27;25(9):4792. doi: 10.3390/ijms25094792.
3
The Cardiopulmonary Complications of Sickle Cell Disease.镰状细胞病的心肺并发症。
Hematol Oncol Clin North Am. 2022 Dec;36(6):1217-1237. doi: 10.1016/j.hoc.2022.07.014.
4
Sickle Cell Disease-Induced Pulmonary Hypertension: A Review of Pathophysiology, Management, and Current Literature.镰状细胞病所致肺动脉高压:病理生理学、管理及当前文献综述
Pulse (Basel). 2021 Sep 23;9(3-4):57-63. doi: 10.1159/000519101. eCollection 2021 Dec.
5
Murine models of sickle cell disease and beta-thalassemia demonstrate pulmonary hypertension with distinctive features.镰状细胞病和β地中海贫血的小鼠模型显示出具有独特特征的肺动脉高压。
Pulm Circ. 2021 Nov 7;11(4):20458940211055996. doi: 10.1177/20458940211055996. eCollection 2021 Oct-Dec.
6
The different facets of sickle cell disease-related pulmonary hypertension.镰状细胞病相关肺动脉高压的不同方面。
Curr Opin Pulm Med. 2021 Sep 1;27(5):319-328. doi: 10.1097/MCP.0000000000000795.
7
Xanthine Oxidase Drives Hemolysis and Vascular Malfunction in Sickle Cell Disease.黄嘌呤氧化酶驱动镰状细胞病中的溶血和血管功能障碍。
Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):769-782. doi: 10.1161/ATVBAHA.120.315081. Epub 2020 Dec 3.
8
PIM1 inhibition attenuated endotoxin-induced acute lung injury through modulating ELK3/ICAM1 axis on pulmonary microvascular endothelial cells.PIM1 抑制通过调节肺微血管内皮细胞上的 ELK3/ICAM1 轴减轻内毒素诱导的急性肺损伤。
Inflamm Res. 2021 Jan;70(1):89-98. doi: 10.1007/s00011-020-01420-3. Epub 2020 Nov 13.
9
HIV X4 Variants Increase Arachidonate 5-Lipoxygenase in the Pulmonary Microenvironment and are associated with Pulmonary Arterial Hypertension.HIV X4 变体增加肺微环境中的花生四烯酸 5-脂氧合酶,并与肺动脉高压相关。
Sci Rep. 2020 Jul 16;10(1):11696. doi: 10.1038/s41598-020-68060-9.
10
Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report.确定镰状细胞肺病的临床和研究重点。美国胸科学会官方研讨会报告。
Ann Am Thorac Soc. 2019 Sep;16(9):e17-e32. doi: 10.1513/AnnalsATS.201906-433ST.